Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

CagriSema vs Mazdutide

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

CagriSema and Mazdutide share the glp-1 class and carry roughly equivalent evidence (Phase 3 / Phase 3 (China)). On the catalogued data layer CagriSema has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; CagriSema's evidence base is currently denser.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

CagriSema

Phase 3

Mazdutide

Phase 3 (China)

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Shared safety considerations

Both compounds share these reported concerns: gi effects. Open each peptide page for the full risk paragraph and source citations.

Side-by-side

CagriSema Mazdutide
Class Amylin + GLP-1 combination GLP-1/glucagon dual agonist
Drug class Metabolic & Weight Metabolic & Weight
Mechanism Dual amylin + GLP-1 receptor agonism Oxyntomodulin analog; activates GLP-1 and glucagon receptors
Route SC injection SC injection
Half-life ~7 days Long-acting weekly
Dosage (research) 2.4 mg / 2.4 mg SC weekly 3-9 mg SC weekly
Evidence tier Phase 3 Phase 3 (China)
Research depth 113 indexed (PubMed 49 · CT 32 · EPMC 32) 126 indexed (PubMed 48 · CT 45 · EPMC 33)
Availability Investigational Investigational
Reported risks GI effects; Phase 3 REDEFINE mixed results GI effects; no Western approval

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick CagriSema or Mazdutide?

CagriSema and Mazdutide share the glp-1 class and carry roughly equivalent evidence (Phase 3 / Phase 3 (China)). On the catalogued data layer CagriSema has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; CagriSema's evidence base is currently denser.

What is the difference between CagriSema and Mazdutide?

CagriSema is classed as Amylin + GLP-1 combination; Mazdutide is classed as GLP-1/glucagon dual agonist. Reported mechanism: CagriSema, Dual amylin + GLP-1 receptor agonism; Mazdutide, Oxyntomodulin analog; activates GLP-1 and glucagon receptors. Reported half-life: CagriSema, ~7 days; Mazdutide, Long-acting weekly. Routes in published studies: CagriSema, SC injection; Mazdutide, SC injection.

Which has stronger evidence, CagriSema or Mazdutide?

CagriSema and Mazdutide sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. CagriSema is graded Phase 3, with 25 cited sources on its reference page and 113 indexed studies. Mazdutide is graded Phase 3 (China), with 23 cited sources on its reference page and 126 indexed studies.

Which is more accessible, CagriSema or Mazdutide?

Neither CagriSema nor Mazdutide is an FDA-approved drug. Catalog status: CagriSema, Investigational; Mazdutide, Investigational.

Are CagriSema and Mazdutide ever combined?

CagriSema and Mazdutide appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…